Skip to main content

Inhibitor of DUX4-IGH to Erase Acute lymphoblastic Leukaemia

Project description

Closing in on a leukaemia inhibitor

Cancer is the second leading cause of death globally. The most common paediatric cancer is a particularly aggressive type of blood cancer, B-cell acute lymphoblastic leukaemia (B-ALL). A genetic alteration is responsible for some of the cases and, recently, researchers discovered a molecule that may stop the rearranged sequence from activating its target genes. However, the question remains whether this inhibitor will prevent the transformation leading to the development of leukaemia. The IDEAL project is going to find out, testing the inhibitor in both cellular and animal models. These preclinical tests are an important step on the path to improving treatment and patient outcomes.


Net EU contribution
€ 171 473,28
Via Olgettina 60
20132 Milano

See on map

Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00